Published in Biotech Business Week, April 23rd, 2007
The symposium will highlight the use of ISA247 for the prevention of transplant organ rejection. The evening will focus on the use of calcineurin inhibitors, the design of ISA247, and the potential for this design to result in improvements in both safety and efficacy for transplant and psoriasis patients. The latest results from the North American Phase 2b kidney transplant (PROMISE) trial will also be presented. The symposium will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.